<DOC>
	<DOC>NCT03082885</DOC>
	<brief_summary>A randomized controlled trial to evaluate efficacy and safety of Thymosin-α1 administration in patients with HBV-related Acute-on-chronic liver failure.</brief_summary>
	<brief_title>The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF.</brief_title>
	<detailed_description>Hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) is a severe disease with high mortality. In this study, we intend to assess the efficacy and safety of Thymosin-α1 in patients with HBV-related Acute-on-chronic liver failure.</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<criteria>1.Chronic hepatitis B. 2.defined by an acute deterioration in Transaminase greater than or equal to 10 NUT time over14 days. 3.development of jaundice (serum bilirubin greater than or equal to 5mg/dl). more than one of the below criteria： 4.development of coagulopathy(INR≥1.5). 5.development of hepatic encephalopathy. 6.development of renal insufficiency(serum creatinine ≥ 2 mg/dl ). 7.Hepatic narrowing. 8.development of massive ascites or peritonitis. 1.Patients who have hepatocellular carcinoma. 2.Patients who have autoimmune disease. 3.Patients with significant comorbid illnesses such as cardiovascular or respiratory or intrinsic renal diseases which by themselves may have a bearing on the outcome. 4.Patients who have disseminated intravascular coagulation. 5.Drug allergy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>